Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 356

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 356
---
 directors; |

| • |     | instituting and overseeing director orientation and director continuing education programs; |

| • |     | serving as a focal point for communication between candidates, 
 non-committee directors and our management;                    |

| • |     | recommending to our Board for selection candidates to serve as nominees for director for the annual meeting of 
 stockholders;                                                                                                  |

| • |     | making other recommendations to our Board regarding matters relating to the directors; |

236

| • |     | reviewing succession plans for our Chief Executive Officer and our other executive officers; |

| • |     | reviewing and overseeing matters of corporate responsibility and sustainability, including potential long- and                               
 short-term trends and impacts to our business of environmental, social, and governance issues, and our public reporting on these topics; and |

| • |     | considering any recommendations for nominees and proposals submitted by stockholders. |

The Nominating and Corporate Governance Committee periodically reviews, discusses and assesses the performance of our Board and the committees of our Board. In fulfilling this responsibility, the Nominating and Corporate Governance Committee seeks input from senior management, our Board and others. In assessing our Board, the Nominating and Corporate Governance Committee evaluates the overall composition of our Board, our Board’s contribution as a whole and its effectiveness in serving our best interests and the best interests of our stockholders. The Nominating and Corporate Governance Committee reviews, discusses and assesses its own performance and composition at least annually. The Nominating and Corporate Governance Committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. The composition and functioning of the Nominating and Corporate Governance Committee comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. Commercialization and Transaction Committee Our C&T Committee consists of Jay Chun, M.D., Ph.D. and Henry Ji, Ph.D., with Dr. Ji serving as the chairperson of the committee. The responsibilities of the C&T Committee are included in a written charter. The C&T Committee (a) assists the Board in its oversight of the Company’s (i) commercial strategy and operations, including product launch preparation and execution, (ii) medical affairs activities, and (iii) research and development (“R&D”) portfolio management and (b